This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1bdq

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1bdq.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1bdq.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1bdq| PDB=1bdq | SCENE= }}
{{STRUCTURE_1bdq| PDB=1bdq | SCENE= }}
-
'''HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386'''
+
===HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386===
-
==Overview==
+
<!--
-
The structural basis of ligand specificity in human immunodeficiency virus (HIV) protease has been investigated by determining the crystal structures of three chimeric HIV proteases complexed with SB203386, a tripeptide analogue inhibitor. The chimeras are constructed by substituting amino acid residues in the HIV type 1 (HIV-1) protease sequence with the corresponding residues from HIV type 2 (HIV-2) in the region spanning residues 31-37 and in the active site cavity. SB203386 is a potent inhibitor of HIV-1 protease (Ki = 18 nM) but has a decreased affinity for HIV-2 protease (Ki = 1280 nM). Crystallographic analysis reveals that substitution of residues 31-37 (30's loop) with those of HIV-2 protease renders the chimera similar to HIV-2 protease in both the inhibitor binding affinity and mode of binding (two inhibitor molecules per protease dimer). However, further substitution of active site residues 47 and 82 has a compensatory effect which restores the HIV-1-like inhibitor binding mode (one inhibitor molecule in the center of the protease active site) and partially restores the affinity. Comparison of the three chimeric protease structures with those of HIV-1 and SIV proteases complexed with the same inhibitor reveals structural changes in the flap regions and the 80's loops, as well as changes in the dimensions of the active site cavity. The study provides structural evidence of the role of the 30's loop in conferring inhibitor specificity in HIV proteases.
+
The line below this paragraph, {{ABSTRACT_PUBMED_9692985}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 9692985 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_9692985}}
==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: Polyprotein]]
[[Category: Polyprotein]]
[[Category: Substrate analogue inhibitor]]
[[Category: Substrate analogue inhibitor]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 11:22:55 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jun 30 18:54:59 2008''

Revision as of 15:55, 30 June 2008

Image:1bdq.png

Template:STRUCTURE 1bdq

HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386

Template:ABSTRACT PUBMED 9692985

About this Structure

1BDQ is a Single protein structure of sequence from Human immunodeficiency virus. Full crystallographic information is available from OCA.

Reference

Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease., Swairjo MA, Towler EM, Debouck C, Abdel-Meguid SS, Biochemistry. 1998 Aug 4;37(31):10928-36. PMID:9692985

Page seeded by OCA on Mon Jun 30 18:54:59 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1bdq"
Personal tools